ALCYON

Science · Norovirus

Norovirus: active and passive immunity, and how they differ

Norovirus establishes infection at the intestinal epithelium. The useful question is therefore not what circulates in the blood, but what is present in the gut lumen, and when it gets there.

Status: IgY: core programme OMV: exploratory · Partner and investor enquiries

01 · The problem

Why norovirus is an intestinal problem

Where it acts

Norovirus infects cells of the intestine. Material that reaches the gut lumen in functional form is present at that site without needing systemic absorption.

How it spreads

Norovirus spreads readily from person to person, through contaminated food, water and surfaces, and a very small number of particles can be enough to start an infection.

Source: US Centers for Disease Control and Prevention, norovirus overview.

Why closed settings differ

On a voyage, a ward or a barracks, the exposure window is bounded and known in advance. In that setting, how quickly something is present matters more than how long it lasts.

The operational view. In a closed setting, an outbreak is first an operational event: rotas, cabin and ward capacity, cleaning cycles, itineraries and reputation. This page is written for the people who carry that responsibility.

02 · The core distinction

Active and passive immunity are not the same thing

Active immunity is what your own immune system builds after it meets an antigen. It takes time and it can be remembered. Passive immunity is antibodies made elsewhere and handed over ready to work. It needs no build-up and leaves no memory.

Active and passive immunity compared
PropertyActive immunityPassive immunity
What is givenAn antigenReady-made antibodies
What the body doesMounts its own response and forms memoryNothing: the antibodies are borrowed
OnsetWeeksOn arrival at the site of action
DurationMonths to yearsDays, only while the material is present
Repeat dosingBoosters, infrequentDosed across the exposure window
Immunological memoryYesNo
Alcyon armOMV-displayed antigen ExploratoryOral IgY Core
Schematic timeline, not measured data. Active immunity begins weeks before an exposure window, rises slowly and then persists for months after it. Passive immunity is absent until dosing starts at the beginning of the window, is present only while it is dosed across the window, and falls away within days after dosing stops. The two modes cover different parts of the timeline, so they complement rather than compete with each other.
Figure 1. Onset and duration of each mode against a bounded exposure window. Schematic only: no measured data are shown.

Note. Passive immunity is not a vaccine and is not a substitute for one.

03 · The passive arm

The passive arm: IgY Core programme

What IgY is

Immunoglobulin Y is the main antibody class in birds and the avian counterpart of mammalian IgG. It is produced by immunised laying hens and transferred into the egg yolk, from which it is recovered. That allows production at scale from eggs rather than from bled animals. Taken by mouth, it is intended to act locally in the intestinal lumen rather than in the bloodstream.

Egg allergen. IgY is recovered from egg yolk and is therefore an egg-derived material. It is not intended for people with egg allergy.

The working chain

Select a step for detail.

  1. Step 1Antigen selection & design

    Choosing and designing the antigen that hens are immunised with. This is where specificity and breadth are intended to be set.

  2. Step 2Hen immunisation

    Laying hens are immunised with the designed antigen on a defined schedule.

  3. Step 3Differentiated polyclonal repertoire

    The hen produces many antibodies against different parts of the antigen, rather than a single clone.

  4. Step 4IgY recovery from yolk

    Antibody is separated from the yolk, with processing designed to keep binding function and not only protein mass.

  5. Step 5Oral formulation & delivery

    The antibody is built into protected particles intended to pass the stomach.

  6. Step 6Functional material in the lumen

    The design goal: antibody that still binds when and where it is released in the intestine.

Antigen design sits upstream of everything else. The antigen chosen is intended to determine the specificity and breadth of the resulting polyclonal preparation, so it is a source of differentiation in its own right, not merely an input borrowed from vaccine work.

  • Antigen selection and design
  • Functional IgY
  • Protected oral delivery

Norovirus is the selected first indication at the centre of these three capabilities.

Protected oral delivery

An antibody taken by mouth faces three separate losses. They act on different properties of the molecule, and protecting against one does not protect against the others:

Loss 1

Gastric loss

Denaturation and protein digestion at low pH in the presence of pepsin.

Loss 2

Process loss

Wetting, shear and drying can leave the molecule intact as protein mass while the antigen-binding site loses its shape.

Loss 3

Storage loss

Aggregation and unfolding driven by residual moisture and molecular mobility in the solid state.

Schematic cross-section of one particle. A matrix core of carbohydrate and amino acid has antibody distributed throughout it. An enteric film surrounds each individual particle. Many such particles are filled into a capsule, sachet or sprinkle presentation, so the barrier is on the particle, not on the container.
Figure 2. Particle architecture: antibody distributed through a carbohydrate and amino-acid matrix core, with an enteric film on each particle. Presentation can be a capsule, sachet or sprinkle.
Why the barrier is on each particle, not on the capsule

A coating on the container is a single point of failure. If the capsule shell cracks, is chewed, or is opened to sprinkle onto food, the whole dose loses its gastric barrier at once.

A film on each particle is designed to keep that barrier independent of the presentation. The same particles can be filled into a capsule, packed in a sachet or sprinkled, and each one still carries its own film. Release is also spread across many small units rather than one.

Technical and IP summaries are available on request. Contact us.

04 · The active arm

The active arm: OMVs Exploratory

Exploratory. Every statement in this section is conditional. No preclinical or clinical work is claimed.

Exploratory

What an OMV is

Outer membrane vesicles are nanoscale vesicles shed from the outer membrane of Gram-negative bacteria. They carry membrane-associated components and are studied as antigen-display platforms with built-in adjuvant properties.

OMVs are already used in a licensed vaccine in another indication: the meningococcal group B vaccine 4CMenB contains an OMV component. Reference to be confirmed before publication.

Exploratory

Why it is interesting here

An OMV would be one route to presenting a designed norovirus antigen to the mucosal immune system. It would draw on the same upstream antigen-design capability that feeds the IgY arm, so work done there may serve both arms.

What is not yet established

  • Antigen format
  • Construct design
  • Route
  • Dose
  • Immunogenicity
  • Safety
  • Manufacturing

All of these are open questions.

Status. Active immunisation is not the immediate product strategy. Knowledge generated through antigen selection may support later investigation of it.

05 · Combining the arms

How the two arms fit together

Now: passive

A bounded, known window

Oral IgY is designed to be present across a bounded exposure window that is known in advance, with an onset that does not depend on weeks of immune build-up.

Later: active

Recurrent exposure

An active approach would be relevant where exposure is recurrent and longer-lasting. It depends entirely on the exploratory arm described above.

Shared foundation: antigen selection and design feeds both arms.

The two answer different questions. Which one fits depends on how long the exposure window is, and how far in advance it is known.

06 · Evidence design

How function is measured

No results are reported on this page. These endpoints describe how evidence will be generated. The programme's data are prospective.

Mass recovered is not function recovered. A preparation can release antibody protein in full and still have a reduced capacity to block attachment. A single "percent released" figure cannot tell those two cases apart.

E1

Physical recovery

How much material is released, and in which compartment.

E2

Retained specific potency

Blocking potency per unit mass recovered, compared with a time-zero control from the same batch, run on the same occasion by the same analyst.

E3

Functional dose recovery

E1 and E2 combined, reported across the intestinal window rather than at a single end point.

The three endpoints are always reported separately and never collapsed into one number.

The transit test

An acid stage with pepsin, a transition in the same vessel, then an intestinal stage with bile salts and pancreatin. It is a comparative method for discriminating between formulations tested in parallel. It is not a validated simulation of human gastrointestinal delivery.

The attachment-blocking assay

Specific to genotype and variant. GII.4 and GII.17 conditions are reported separately and never pooled.

Limitation. This assay does not establish neutralisation, mucosal immunity, prevention, treatment, symptom reduction or reduced viral shedding. A result supports only the exact condition tested.

07 · Settings

Where a bounded exposure window matters

Lead case

Cruise and closed settings

A voyage is a defined window. An outbreak has operational and reputational consequences for the operator, who may be the economic beneficiary rather than the individual passenger.

What we would need to validate: outbreak economics, who buys and who pays, and which claims are permitted.

Hypothesis

Travel

Some travellers may prefer an oral format to an injection. This is a commercial hypothesis, not a finding.

What we would need to validate: stated preference and willingness to pay.

Unvalidated

Institutional and deployment settings

Value depends on how long a deployment lasts and on actual exposure, so this setting needs segmenting before any conclusion.

What we would need to validate: segmentation by duration and exposure.

08 · Regulatory

Regulatory position, and what we do not claim

The route under investigation is a food-supplement-first strategy. It is not confirmed, and it remains subject to review by qualified regulatory counsel.

We make no claim that any Alcyon product prevents, treats, cures or reduces the risk of norovirus infection or of any other disease. Nothing on this page is medical advice. Availability, if any, varies by jurisdiction.

Read the full legal and claims statement

09 · Programme

Programme status

In progress

Antigen selection

Choosing and designing norovirus antigens for hen immunisation, with GII.4 and GII.17 in scope.

Planned

IgY generation & characterisation

Immunisation, yolk recovery and binding characterisation of the resulting polyclonal IgY.

Planned

Formulation & transit testing

Protected particles, assessed with the two-stage transit test and endpoints E1 to E3.

Planned

Evidence package

A consolidated, reviewable dataset to support regulatory and partner discussions.

What would move this forward: laboratory partners for antigen production and hen immunisation, and seed funding for the first IgY batches. Talk to us.

10 · FAQ

Questions we are asked

Is this a vaccine?

No. A vaccine drives active immunity: the body's own response and its own memory. IgY is passive. The antibodies are made by hens, and no immunological memory is formed.

How quickly would it act, and for how long?

Mechanistically, passive material can only act where and while it is present, and it stops when it is cleared. We will not give timing figures until evidence exists.

I am allergic to eggs. Could I take it?

IgY is recovered from egg yolk, so the material is egg-derived. It is not intended for people with egg allergy.

Is it approved?

No. There is no product on the market and no regulatory authorisation. The programme is at the research and development stage.

Why hens rather than mammals?

Antibody is recovered from egg yolk. That allows production at scale from eggs collected in the normal way, without bleeding animals.

What is an OMV, and why is it on this page? Exploratory

An outer membrane vesicle is a nanoscale vesicle shed by Gram-negative bacteria and studied as an antigen-display platform. It is the exploratory active-immunisation arm described above. It is not the immediate product strategy.

Where can I read the technical detail?

Technical and intellectual-property summaries are available to partners, investors and collaborators on request. Use the contact form and choose the route that fits.

Contact

Talk to us

For cruise and institutional partners, investors, and scientific collaborators or candidates. Choose a route and we will send your message to the right person.

We aim to reply within five working days.